– Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million –– GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 –– Conference […]
Tag: Exelixis
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
– Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million – – GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.26 – […]